Candel Therapeutics一度爆升140%，新药三期试验达到主要目标
周三，医药公司Candel Therapeutics一度爆升超140%，截至发稿，该股涨121%。公司发布了其针对中至高风险局部前列腺癌患者的三期临床试验结果，该试验聚焦于CAN-2409病毒免疫治疗。结果显示，该试验已达到其主要终点，并显著表明，相较于仅接受标准治疗的患者，联合使用CAN-2409与前药伐昔洛韦及标准治疗的患者在无病生存期方面表现出统计学上的显著改善。CAN-2409与伐昔洛韦的结合疗法旨在通过活化肿瘤微环境并促使肿瘤抗原暴露，从而诱导肿瘤细胞的免疫原性细胞死亡。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10